FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/22/2024
Back to search
Official data from USPTO
BSP PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
BSP PHARMACEUTICALS
ST13
US500000079355934Class
5, 42
Filing
79355934
Registration
7282466
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
05/22/2024
Classification
Registered
Trademark type
Word
Nice classes
5, 42
Filing date
11/02/2022
Registration date
01/23/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/23/2024
Last transaction
01/23/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
35
Owner location
IT
Examiner
MASON,JARED MICHAEL
Law office
N10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
BSP PHARMACEUTICALS S.p.A.
Representatives
James L. Scott Privus PLC
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical products for the treatment of cancer
Class 42
Research and development services in the medical and pharmaceutical fieldspharmaceutical research and development; services for the development and testing of pharmaceutical productsfor third parties
Publications
History of USPTO decisions and trademark events.
25 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/25/2024
FIMP
FINAL DISPOSITION PROCESSED
04/25/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/23/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/23/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
01/23/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/07/2023
PUBO
PUBLISHED FOR OPPOSITION
11/07/2023
GPNX
NOTIFICATION PROCESSED BY IB
11/06/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/18/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
10/18/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/18/2023
RFNT
REFUSAL PROCESSED BY IB
10/04/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/02/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/13/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/12/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/12/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/07/2023
RFRR
REFUSAL PROCESSED BY MPU
09/07/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/18/2023
CNRT
NON-FINAL ACTION WRITTEN
08/17/2023
DOCK
ASSIGNED TO EXAMINER
08/17/2023
MAFR
APPLICATION FILING RECEIPT MAILED
11/29/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/25/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/24/2022
Continuous trademark protection
Get notified about every new filing that threatens BSP PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.